2457 Pill - yellow oval, 18mm
Generic Name: sotagliflozin
Pill with imprint 2457 is Yellow, Oval and has been identified as Inpefa 400 mg. It is supplied by Lexicon Pharmaceuticals, Inc.
Inpefa is used in the treatment of Heart Failure; Chronic Kidney Disease; Type 2 Diabetes and belongs to the drug class SGLT-2 inhibitors. Inpefa 400 mg is not a controlled substance under the Controlled Substances Act (CSA).
Images for 2457
Inpefa
- Generic Name
- sotagliflozin
- Imprint
- 2457
- Strength
- 400 mg
- Color
- Yellow
- Size
- 18.00 mm
- Shape
- Oval
- Availability
- Prescription only
- Drug Class
- SGLT-2 inhibitors
- CSA Schedule
- Not a controlled drug
- Labeler / Supplier
- Lexicon Pharmaceuticals, Inc.
- National Drug Code (NDC)
- 70183-0240 (Discontinued)
See also:
Ozempic
Learn about Ozempic (semaglutide) for type 2 diabetes treatment, weight management, cardiovascular ...
Rybelsus
Rybelsus tablets are used to improve blood sugar control in adults with type 2 diabetes, and may ...
Mounjaro
Mounjaro is used to treat type 2 diabetes in adults. It is a subcutaneous injection that can be ...
Jardiance
Jardiance (empagliflozin) is used to treat type 2 diabetes, chronic kidney disease and reduce the ...
Farxiga
Farxiga (dapagliflozin) is an oral prescription medication that may be given to certain adults with ...
Lasix
Lasix is a loop diuretic used to treat fluid retention from heart, liver, or kidney conditions, and ...
Entresto
Entresto is an oral combination heart medication that contains two blood pressure-lowering ...
Trulicity
Trulicity is an injectable diabetes medicine that is used together with diet and exercise to ...
Wegovy
Wegovy (semaglutide) an FDA-approved weekly injection for weight loss and to reduce heart risks ...
More about Inpefa (sotagliflozin)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: SGLT-2 inhibitors
- En español
Patient resources
Professional resources
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.